BMRA (Biomerica) Tariff Resilience Score: 5/10 (As of Aug. 01, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BMRA Biomerica Inc BMRA
50 GF Score
Price $1.49
GF Value $2.18
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Biomerica Tariff Resilience Score?

Biomerica BMRA -6.28% 50 Tariff Resilience Score is 5 as of Aug. 01, 2026. GuruFocus rates BMRA with a GF Score™ of 50/100 and a GF Value™ of $2.18 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 830 Medical Devices & Instruments companies, Biomerica ranks better than 79.16% on this metric.

Biomerica has the Tariff Resilience Score of 5, which implies that the company might have Average Resilient.

Biomerica has Healthcare company with global supply chain dependencies. Vulnerable to tariffs on medical supplies but can mitigate through alternative suppliers and strategic pricing.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Biomerica might have Average Resilient.

Biomerica  (NAS:BMRA) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Biomerica Tariff Resilience Score Related Terms

BMRA vs WOK, ALURD, ITOC: Tariff Resilience Score Comparison

For the Medical Devices subindustry, Biomerica's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biomerica Tariff Resilience Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Biomerica's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Biomerica's Tariff Resilience Score falls into.


BMRA
50GF Score
Biomerica Inc BMRA
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 5 mean?
Biomerica (BMRA) has a Tariff Resilience Score of 5 as of Aug. 01, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Biomerica ranks #173 out of 830 companies in the Medical Devices & Instruments industry, placing it in the top 20.8%.
Is Biomerica's Tariff Resilience Score too high?
Biomerica's current Tariff Resilience Score is 5. Based on the distribution chart, Biomerica ranks #173 out of 830 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Biomerica has a GF Score™ of 50/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Biomerica's Tariff Resilience Score compare to WOK and ALURD?
According to the Medical Devices & Instruments industry distribution chart, Biomerica ranks #173 out of 830 companies for Tariff Resilience Score. This places Biomerica in the top 21% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Medical Devices & Instruments company?
A good Tariff Resilience Score depends on the Medical Devices & Instruments industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. Biomerica's current Tariff Resilience Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biomerica stock overvalued right now?
Based on GuruFocus' analysis, Biomerica (BMRA) is currently considered Possible Value Trap. The stock's GF Value™ is $2.18, compared to a current price of $1.49 — trading 31.7% below its estimated fair value. The current Tariff Resilience Score is 5. Biomerica's overall GF Score™ is 50/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Biomerica (BMRA), the current Tariff Resilience Score is 5 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biomerica (BMRA) Overvalued in 2026?

Based on GuruFocus' analysis, Biomerica stock appears to be undervalued. The current stock price of $1.49 is trading 31.7% below its estimated GF Value™ of $2.18. GuruFocus considers Biomerica to be Possible Value Trap.

Key valuation signals for BMRA:

  • Tariff Resilience Score: 5
  • GF Value™: $2.18 vs. price of $1.49 (31.7% below fair value)
  • GF Score™: 50/100 with 5 warning signs

No single metric tells the full story. See the BMRA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biomerica Business Description

Address 17571 Von Karman Avenue, Irvine, CA, USA, 92614
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. The Company manages its operations as a single operating and reportable segment, which focus on the development, manufacture, marketing, and sale of diagnostic products. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America.
50GF Score

Get the complete analysis for BMRA

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.49
Price
$2.18
GF Value